FDA
-
-
-
-
-
-
-
Sana Biotechnology Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates
-
-
-
-
-
-
-
Sana Biotechnology (SANA) Announces Fast Track Designation for SC291 in Relapsed/Refractory Systemic Lupus Erythematosus
-
-
-
-
-
-
-
Sana Biotechnology (SANA) Announces FDA Clearance of Investigational New Drug Application for SC291
-
-
-
-
-
-
-
Sana Biotechnology (SANA) Announces FDA Clearance of Investigational New Drug Application for SC291
-
-
-
-
-
-
-
Alltrna Appoints Rare Disease Clinical Research Expert, Dr. Anne Pariser, as Vice President, Medical and Regulatory Affairs
-
-
-
-
-
-
-
Dr. Stephen Hahn, 24th US FDA Commissioner and Former Chief Medical Executive at MD Anderson, joins Flagship Pioneering as Chief Medical Officer of Flagship's Preemptive Medicine and Health Security I
328,165 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

